Public company

On incorporation, a small, family-owned firm may start with an initial capital of 10,000 divided into 10,000 shares of 1 each. A large public company, on the other hand, may have a share capital of many millions of dollars, sub-divided into many more millions of shares or stock units, of perhaps as little as 25 cents. 

N. J. Turro, Modern Molecular Photochemistry, Benjamin/Cummings Publication Company, Menlo Park, NJ, 1978 J. Michel and V. Bonacic-Koutecky, Electronic Aspects of Organic Photochemistry, Wiley-Interscience, New York, 1990. 

Ward s Business Directory of United State private and public companies, Gale research incorporated, United State, 1983. 

This is UPS s growth story from its birth in 1907 in Seattle, Washington when nineteen-year-old Jim Casey started a messenger and home delivery service for city department stores. Today UPS is a global public company with more than 36 billion of revenue, and operations in over 200 countries and territories. 

UPS became a public company in 1999, going public in the largest IPO in the history of the New York Stock Exchange. Today, about half of UPS stock is owned by its current and former employees and their families. UPS has a market capitalization of 46 billion and is one of only seven public companies with an AAA credit rating from both S P and Moodys. 

The first major attempt to evaluate the quality of business operating results was the Stern Stewart EVA computation, a proprietary complicated formula that can make up to 160 adjustments to reported earnings of public companies. A component of EVA is to determine a firm s net operating income after tax and while it may accomplish this objective, it has been criticized because it relies on data that, as stated earlier, can be managed (Brewer Chandra, 1999). It was more than a decade before Wall Street analysts accepted EVA, and today its use is widespread in the corporate world, but not as much as in the investment world. 

Jean-Marc Sabatier has a Ph.D. and HDR in biochemistry. He is the director of research at the French Centre National de la Recherche Scientifique (CNRS). He heads a research laboratory (ERT 62) entided Engineering of Therapeutic Peptides at the Universite de la Mediterranee, in Marseilles, France. He also holds the position of a senior director (discovery research — peptides) for a public company in Canada. Dr. Sabatier works in the field of animal toxins, and leads the venom peptide group of the International Neuropeptide Society. He also designs immunomodulatory and antiviral drugs, as well as contributes to the field of peptide and protein engineering. He has contributed more than 100 scientific articles, 180 communications, and 43 patents. He is a member of several scientific advisory boards of journals (e.g.. Peptides, Biochemical Journal), and has reviewed articles submitted for publication in more than 30 specialized international journals. 

Sasol is now a public company and its shares are listed on the Johannesburg Stock Exchange. Despite the fluctuations in the price of crude oil, the commercial success of the process is reflected by the four-fold increase in the share prices since 1979. The reason for the viability of the process in South Africa is the combination of three factors ... 

The parallel for a rapidly growing company is the need for investments in manufacturing, larger premises for administration and a broader portfolio of products. When personal maturity comes to the young person, it brings with it a steady income yet many dependants there is a need to consolidate investments and provide for the long term. On the other hand, for the mature public company there is no option to consolidate and still provide a nearly steady income. Only by continued growth can the company maintain or increase its value. This is the imperative under which most companies are run and is the stimulus for business development activities across the board. 

Fig. 30.1 Value of chemical buyout transactions involving public companies with disclosed transaction value, 1986-2004.

Chemical buyout transactions where public companies have been involved as seller or acquirer. 

Fig. 30.2 Chemical buyout transactions involving public companies by subsegment and by region, 1986-2004.

J. Spanier, E.M. Gelbard Monte Carlo Principles and Neutron Transport Problems (Addison Wesley Publication Company 1969)... 

H. Rupprecht, Physical-chemical basics of freeze-drying, in Lyophilisation. (Essig, Oschmann, ed). Scientific Publication Company, Stuttgart, 1993, p. 29. 

Kauffman, G. B., Editor, Classics in Coordination Chemistry. Part I. The Selected Papers of Alfred Werner, Dover Publication Company, New York, 1966. 

Nobel Lectures in Chemistry, 1901-1962, Nobel Foundation, 1 (1901-1921), American-Elsevier Publication Company, Inc., New York, N. Y., 1966. 

Wilcox, Frank U.DNA The Thread of Life. Minneapolis Lem-er Publications Company, 1988. 

N. Handa and T. Ohsumi, (eds). Direct Ocean Disposal of Carbon Dioxide, Terra Scientific Publication Company, Tokyo, 1995. 

Governance Forces The Public Company Accounting Reform and Investor Protection Act of 2002 (also known as the Sarbanes-Oxley Act, Public Law 107-204) was passed after the well-publicized corporate governance failures starting in 2001.The intent of the act was to strengthen corporate governance and financial disclosure rules under the Security and Exchange Commission s (SEC) rules for publicly traded companies. 

Information available to healthcare professionals Promotional material must be accessible to healthcare professionals only via a secure system that is designed to prevent access by members of the general public. Companies must take all reasonable steps to ensure that these information sources are appropriate and will enhance the appropriate prescribing, dispensing and usage of medicines in Australia. Any promotional material provided to healthcare professionals via the internet must comply with the requirements for other promotional items. 

Pharmaceutical physicians in large pharmaceutical companies will only very rarely be exposed to the need for press releases concerning their clinical trials. In contrast, the small entrepreneurial pharmaceutical company may live or die on the outcome of a single clinical trial. The rapid dissemination of the results of such a clinical trial to the appropriate audience (shareholders and investment community) is legally required when material to the prospects of a small, public company. The press release then becomes an important tool for publishing clinical trial results. 

J. K. Ousterhout, Tcl and Tk Toolkit, Addison-Wesley Publication Company, Reading, 1994. 

Deutsch, D. J. and the Staff of Chemical Engineering, Microcomputer Programs for Chemical Engineers, McGraw-Hill Publication Company, New York, NY, 1984. 

In the United States, public companies are required to report their financial performance quarterly, with an annual report required at the end of the fiscal year. Non-U.S. companies with a stock trading on a U.S. stock exchange must also file quarterly and annual statements. Even foreign, public companies not on a U.S. exchange file annual reports for use by investors, analysts, and employees. Annual and quarterly reports are often found on the companies websites listed under investor relations. In the United States, these reports are available from the Securities and Exchange Commission (http //www.sec.gov) at no charge. Financial information on private companies is much more difficult to find. Users must depend on disclosure by the private company or rely on primary research vendors for information. 

Dun s Financial Records Plus . The D B Corporation, 103 JFK Parkway, Short Hills, NJ 07078, U.S.A. Phone +1 800-234-3867. E-mail custserv dnb.com. URL http //www.dnb. com. D B collects information on 75 million firms in 214 countries around the world. In addition to public companies, D B also covers private companies who submit their data to D B. Dun s Financial Records Plus (available online from DIALOG) has three years of comprehensive financial information. 

---